TheraRadar
← Back
Data updated: Sep 20, 2026

DEVA HLDING

Generics
Pharmaceuticals

DEVA HLDING is a generic drug manufacturer with 1 FDA-approved products.

2026
Since
1
Drugs
-
Trials
2
New Drugs (2yr)

DEVA HLDING's Key Drugs

DEVA HLDING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

DEVA HLDING's Recent FDA Approvals

DEVA HLDING secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

DEVA HLDING's Therapeutic Areas

Disease areas where DEVA HLDING has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

DEVA HLDING Pipeline Snapshot

Active clinical trials for DEVA HLDING across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling